


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. St. Catherine Hospital, Inc.</p>	<p>In accordance with letter dated October 08, 2020,</p>	<p>4. Expiration Date: November 30, 2025</p>
<p>2. 4321 Fir St. East Chicago, IN 46312</p>	<p>3. License No.: 13-01148-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-01590 Reference No.:</p>

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie total	C. For any use permitted by 10 CFR 35.300.
D. Any byproduct material permitted by 10 CFR 31.11	D. Prepackaged Kits	D. 5 millicuries total	D. For use in in-vitro studies.



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-01148-01

Docket or Reference No.:
030-01590

Amendment No. 80

- | | | | |
|-------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use |
| E. Yttrium-90 permitted by 10 CFR 35.1000 | E. Microspheres (Sirtex Medical Limited, Sirtex Wilmington LLC, Sirtex Singapore Manufacturing Pte Ltd, Model SIR-Spheres) | E. 3 curies total | E. For medical use, as permitted by 10 CFR 35.1000, in a Sirtex Medical Limited brachytherapy afterloader delivery system. |

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 4321 Fir St., East Chicago, Indiana, 46312.
11. The Radiation Safety Officer (RSO) for this license is Santosh K. Kar, M.S.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)

Material and Use

Ravi S. Bhagwat, M.D.	10 CFR 35.100,10 CFR 35.200
Dean Michael Ferrera, D.O.	10 CFR 35.200
John W. Gustaitis, Jr., M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Thomas M. Hoess, M.D.	10 CFR 31.11,10 CFR 35.100,10 CFR 35.200
Omar Hussein, M.D.	10 CFR 35.200
Mikhail Jeha, M.D.	10 CFR 31.11,10 CFR 35.100,10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-01148-01

Docket or Reference No.:
030-01590

Amendment No. 80

Authorized User (M.D.,D.O.,etc.)Material and Use

Shawn R. Kenney, M.D.

10 CFR 31.11,10 CFR 35.100,10 CFR 35.200

Mohan Kesani, M.D.

10 CFR 35.100,10 CFR 35.200

Mohammed M. Khadir, M.D.

10 CFR 35.1000 (limited to yttrium-90 as SIR-Spheres)

Ernest J. Laney, IV, M.D.

10 CFR 35.200

Sorin Lazar, M.D.

10 CFR 35.200

Jonathon T. Lee, M.D.

10 CFR 31.11,10 CFR 35.100,10 CFR 35.200

Mary Nicholson, M.D.

10 CFR 35.100,10 CFR 35.200

Charles-Lauwanga Okoro, D.O.

10 CFR 35.200

Michele Semin, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)

Justin Spackey, M.D.

10 CFR 35.100,10 CFR 35.200

Lingyun Xiong, M.D.

10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)

Ramana Yedavalli, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.1000 (limited to yttrium-90 as SIR-Spheres)

Andrej Zajac, M.D.

10 CFR 35.300

Feng Zhang, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)

13. In accordance with letter dated October 8, 2020 (ML20288A490), the licensee may make changes to its radiation protection program for uses of yttrium-90 permitted by 10 CFR 35.1000.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**


License No.: 13-01148-01

Docket or Reference No.:
030-01590

Amendment No. 80

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated June 3, 2015 (ML15159A392)
- B. Letter dated October 23, 2015 (ML15300A589)
- C. Letter dated March 12, 2019 (ML19078A183)
- D. Letter dated April 10, 2019 (ML19101A252)
- E. Letter dated June 17, 2019 (ML19172A213)
- F. Letter dated October 8, 2020 (ML20288A490)
- G. Letter dated November 20, 2020 (ML20329A362)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: January 12, 2021

By: _____

Sara A. Forster
Region III